The Liver Meeting 2024

San Diego, California, US 15 November 2024 - 19 November 2024

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

07 Jan 2025 by

The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

07 Jan 2025

Elafibranor improves transplant-free survival in patients with PBC

14 Dec 2024 by

Among patients with primary biliary cholangitis (PBC), treatment with elafibranor improved predicted transplant-free survival rates based on improvements in GLOBE and UK-PBC scores, according to the phase III ELATIVE trial presented at The Liver Meeting 2024.

Elafibranor improves transplant-free survival in patients with PBC

14 Dec 2024

Odevixibat shows rapid, sustained benefits in patients with ALGS

12 Dec 2024 by

Treatment with odevixibat led to rapid and sustained improvements in pruritus and serum bile acid (sBA) levels among patients with Alagille syndrome (ALGS), according to the ﬁnal data of the phase III ASSERT-extension (ASSERT-EXT) study presented at The Liver Meeting 2024.

Odevixibat shows rapid, sustained benefits in patients with ALGS

12 Dec 2024

Pooled analysis ASSUREs seladelpar role in PBC

04 Dec 2024 by

Results of the phase III ASSURE study support seladelpar – a novel first-in-class delpar (selective peroxisome proliferator-activated receptor delta agonist) – for the treatment of primary biliary cholangitis (PBC).

Pooled analysis ASSUREs seladelpar role in PBC

04 Dec 2024

Beer drinkers have it worse diet-wise than other alcohol drinkers

02 Dec 2024 by

Among consumers of different types of alcohol, those who consume beer only have the lowest dietary quality compared with those confined to wine or liquor intake or those who consume multiple types of alcohol, according to data presented at TLM 2024.

Beer drinkers have it worse diet-wise than other alcohol drinkers

02 Dec 2024

Statins confer protection against portal hypertension, mortality in cirrhosis

01 Dec 2024 by

Statins appear to be beneficial to patients with cirrhosis, being associated with reduced risks of portal hypertension and its complications as well as death, according to a study.

Statins confer protection against portal hypertension, mortality in cirrhosis

01 Dec 2024

Sex-based gap in liver transplant allocation narrowed with MELD 3.0

28 Nov 2024 by

More women are now being included in liver transplant waitlist and undergoing the procedure following the adoption of the updated Model for End-Stage Liver Disease (MELD)—MELD 3.0—with mortality and transplant rates nearly matching those observed in men, according to a retrospective study conducted in the US.

Sex-based gap in liver transplant allocation narrowed with MELD 3.0

28 Nov 2024

Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis

27 Nov 2024 by

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.

Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis

27 Nov 2024

Alcoholic drinks up risk of death in young adults with MASLD

26 Nov 2024 by

Young adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who drink alcoholic beverages are at greater risk of mortality and of having an unhealthy liver, reports a study presented at AASLD 2024.

Alcoholic drinks up risk of death in young adults with MASLD

26 Nov 2024